LobbyingChattem, Inc D/B/A Opella lobbying by quarter
Chattem, Inc D/B/A Opella's latest lobbying report covers Q2 2026, at $200K. The four quarters Q4 2025–Q3 2026 total $510K. Its first report covers Q1 2025; the issues it reports most are Health Issues and Trade (Domestic & Foreign).
Chattem, Inc D/B/A Opella
- Latest quarter
- No record
- Q3 2026 · 0 reports
- Last 12 months
- $510K
- Last 4 quarters
- vs last quarter
- −100.0%
- Q3 2026 against the quarter before
- First report
- Q1 2025
- The first quarter a report named it
Lobbying by quarter
| Quarter | Amount | Reports |
|---|---|---|
| Q1 2025 | $230K | 1 |
| Q2 2025 | $180K | 1 |
| Q3 2025 | $160K | 1 |
| Q4 2025 | $160K | 1 |
| Q1 2026 | $150K | 1 |
| Q2 2026 | $200K | 1 |
| Q3 2026 | $0 | 0 |
By issue
- Health issues$596.7K · 6 reports
- Trade$276.7K · 4 reports
- Consumer protection and safety$156.7K · 2 reports
- Budget and appropriations$50K · 1 reports
An issue's amount splits each report's amount equally over the issues the report lists.
Who was lobbied
- HOUSE OF REPRESENTATIVES6 reports
- SENATE5 reports
- Food & Drug Administration (FDA)1 reports
Firms it paid
| Firm | ||
|---|---|---|
| In-houseChattem, Inc D/B/A Opella | $1.1M | 6 quarters |
Former officials lobbying for it
No lobbyist with a covered position.
Lobbying reports
| Filed by | ||
|---|---|---|
| 07/16for Q2 | In-house | $200K |
| 04/20for Q1 | In-house | $150K |
| 01/19for Q4 2025 | In-house | $160K |
| 25/10/15for Q3 2025 | In-house | $160K |
| 25/07/18for Q2 2025 | In-house | $180K |
| 25/04/17for Q1 2025 | In-house | $230K |
| 25/03/11for Q1 2025 | In-house | Under $5,000 |